Hirsutism, drug-induced

L12_HIRSUTISM_ADVERSE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ATC codes for adverse effects of Drugs — ANY
  • Hospital discharge: ICD-10 — L68.0#

1 out of 7 registries used, show all original rules.

67

4. Check minimum number of events

None

67

5. Include endpoints

None

67

6. Filter based on genotype QC (FinnGen only)

62

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
C
First used in FinnGen datafreeze
DF5
Parent code in ICD-10
L68
Name in latin
Hirsutismus

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (not available in FinRegistry).

-FinnGen-

Key figures

All Female Male
Number of individuals 62 62 -
Unadjusted period prevalence (%) 0.02 0.02 -
Median age at first event (years) 32.95 32.95 -

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
67
Matched controls
670
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L68.0
ICD-10 Finland
Hirsutism
+∞
91.5
67
*
G03HB01
ATC
cyproterone and estrogen; oral
10.2
21.1
37
72
G03DB01
ATC
dydrogesterone; oral
5.5
11.1
34
105
C03DA01
ATC
spironolactone; oral
10.4
10.9
22
30
T90
ICPC
Diabetes non-insulin dependent
4.9
8.4
25
73
XLA10, ,
NOMESCO Finland
9.1
8.1
17
24
215
Kela drug reimbursment
Diabetes, non-insulin-treated
4.7
7.9
24
71
103
Kela drug reimbursment
Diabetes, insulin-treated
4.6
7.7
24
72
G03HA01
ATC
cyproterone; systemic
+∞
7.4
7
*
E28.2
ICD-10 Finland
Polycystic ovarian syndrome
16.1
7.2
11
8
A10BA02
ATC
metformin; oral
4.0
6.7
26
91

TimeCodeWAS

↥

TimeCodeWAS is a tool for exploring time-dependent associations between an endpoint and health codes (diagnoses, lab tests, procedures, etc.).

The TimeCodeWAS analysis is done in three steps:

  1. Build a matched case-control set for this endpoint. Each case is matched to 5–10 controls on sex and year of birth, and controls must be at risk at the same age as the case's age of onset. TimeCodeWAS allows for controls to be reused.
  2. Count cases and controls. For each health code, and for each time window: tally the counts into a 2×2 table. To be eligible in a time window, a case or control must have data coverage for at least 50% of that time window.
  3. Perform association tests. If all cells of the 2×2 table have N≥10, then a χ² test is performed, otherwise a Fisher's exact test is done. The corresponding p-value and confidence interval are reported below, along with the standard odds ratio when a χ² test is done, or Fisher's MLE odds ratio otherwise.

TimeCodeWAS currently uses the same default set of time windows for all the endpoints. Please reach out to us if you have suggestions for better time windows for some endpoints. The default time windows are: TimeCodeWAS time windows

Sort & Filter
Sort
Odds Ratio
among windows:
Filter
Code & OMOP
Cases and controls with code
in
Odds Ratio
in
OMOP Concept
Code (OMOP Vocabulary) [OMOP Concept ID]
OMOP Concept Class / OMOP Domain
Odds Ratio
TimeCodeWAS O.R. time legend
Cases and controls with code
TimeCodeWAS Cases and Controls percentages time legend
cyproterone and estrogen
G03HB01 (ATC) [21602617]
ATC 5th / Drug
1.8e+00 — — — 2.7e+00 3.5e+00 2.4e+00
19.40%/3.73% —/— —/— —/— 10.45%/0.75% 28.36%/1.20% 37.31%/4.95%
Obstetrics / Gynecology
16 (Medicare Specialty) [38004461]
Physician Specialty / Provider
-3.6e-02 5.8e-02 — 1.0e+50 2.4e+00 1.8e+00 4.9e-01
28.36%/29.10% 11.94%/11.34% —/— 76.12%/0.00% 20.90%/2.24% 47.76%/13.45% 46.27%/34.53%
Outpatient Visit
OP (Visit) [9202]
Visit / Visit
1.5e-01 9.0e-01 7.3e-01 — 2.4e+00 2.1e+00 7.5e-01
22.39%/19.85% 43.28%/23.73% 11.94%/6.12% —/— 41.79%/6.12% 76.12%/29.00% 74.63%/58.26%
oxazepam; oral
N05BA04 (ATC) [21604569]
ATC 5th / Drug
2.4e+00 — — — — — —
7.46%/0.75% —/— —/— —/— —/— —/— —/—
Pharmacy visit
OMOP4822462 (Visit) [581458]
Visit / Visit
7.0e-01 7.4e-01 7.4e-01 2.4e+00 1.6e+00 1.3e+00 —
92.54%/85.97% 80.60%/66.42% 34.33%/20.00% 7.46%/0.75% 53.73%/18.81% 88.06%/66.67% —/—
zopiclone; oral
N05CF01 (ATC) [21604654]
ATC 5th / Drug
2.1e+00 — — — — 2.2e+00 1.3e+00
8.96%/1.19% —/— —/— —/— —/— 8.96%/1.05% 7.46%/2.25%
dydrogesterone; oral
G03DB01 (ATC) [21602544]
ATC 5th / Drug
2.2e+00 1.6e+00 — — — — 1.2e+00
25.37%/3.58% 7.46%/1.64% —/— —/— —/— —/— 11.94%/3.75%
sertraline; oral
N06AB06 (ATC) [21604714]
ATC 5th / Drug
— — — — — — 2.1e+00
—/— —/— —/— —/— —/— —/— 10.45%/1.35%
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X (NUCC) [38003841]
Physician Specialty / Provider
-1.0e+50 — — — — 1.9e+00 9.4e-01
0.00%/1.49% —/— —/— —/— —/— 10.45%/1.64% 13.43%/5.71%

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
29
142
2.84
4.07
4.2
3.3
1.43
5.03
mg/mmol
0.71
17
75
29
142
2.84
4.07
3.6
2.9
8.89
27.37
mg/l
0.98
15
81
7
17
4.47
2.43
5.3
6.4
—
—
—
0
0
8
23
3.80
2.35
1.0
1.3
—
—
—
0
0
18
91
2.34
2.21
2.5
2.9
6.60
205.06
ng/l
—
10
51
27
167
2.03
2.00
4.6
3.1
7.43
7.40
ph
2.59
18
112
11
48
2.55
1.82
5.5
4.4
4.36
4.53
pmol/l
0.31
11
43
10
41
2.69
1.73
1.3
1.2
—
—
—
0
0
38
284
1.78
1.47
1.9
1.8
1.79
1.35
mmol/l
1.74
33
250
5
16
3.29
1.46
2.2
1.4
60.20
93.25
ng/l
—
5
16
0
37
0.00
1.39
0.0
1.5
—
295.77
—
0
22
33
242
1.72
1.33
2.3
1.8
91.00
101.93
pmol/l
0.67
14
135
23
152
1.78
1.33
2.0
1.8
0.58
1.16
mg/l
0.70
18
125
30
217
1.69
1.25
3.8
3.1
2.37
2.36
mmol/l
0.20
30
206
28
203
1.65
1.14
2.4
3.2
8.33
17.05
ng/l
2.31
14
103
41
329
1.63
1.10
4.1
5.0
2.04
1.90
e9/l
0.48
36
293
24
171
1.63
1.03
2.2
3.3
—
—
—
0
0
0
28
0.00
1.00
0.0
1.6
—
0.00
—
0
10
11
175
0.56
0.96
1.9
2.3
—
—
—
0
0
23
165
1.60
0.95
1.5
1.4
8.63
27.86
iu/ml
—
8
54
24
176
1.57
0.90
1.5
1.3
2.54
1.85
u/ml
—
7
51
21
152
1.56
0.83
1.5
1.5
23.81
20.65
nmol/l
0.48
21
136
53
469
1.62
0.81
7.8
7.5
75.38
76.72
u/l
0.15
53
438
21
154
1.53
0.78
1.4
1.4
1.11
10.24
u/ml
1.37
13
67
45
387
1.50
0.76
5.6
4.3
—
677.00
—
0
5
8
129
0.57
0.73
1.1
1.6
—
—
—
0
0
13
183
0.64
0.68
1.6
1.5
—
—
—
0
0
24
189
1.42
0.62
1.9
2.8
0.00
0.00
estimate
—
5
58
0
20
0.00
0.61
0.0
1.1
—
—
—
0
0
0
20
0.00
0.61
0.0
1.1
—
—
—
0
0
38
325
1.39
0.60
3.0
3.6
0.00
0.00
estimate
—
5
69
6
96
0.59
0.57
1.3
1.5
—
—
—
0
0
6
99
0.57
0.57
1.0
1.2
—
—
—
0
0
12
83
1.54
0.56
1.7
1.2
—
—
—
0
0
24
292
0.72
0.56
3.2
2.7
—
—
estimate
—
0
0
24
192
1.39
0.56
4.5
4.6
—
—
—
0
0
16
119
1.45
0.55
2.4
2.4
2.44
2.43
mmol/l
0.02
16
109
37
324
1.32
0.46
3.1
3.5
0.00
0.00
estimate
—
5
69
6
91
0.63
0.46
1.0
1.4
—
—
—
0
0
15
191
0.72
0.45
2.5
2.3
—
—
—
0
0
33
286
1.30
0.44
7.2
8.8
0.00
0.00
e9/l
0.86
25
227
5
33
1.56
0.42
1.8
1.1
0.78
0.85
g/l
—
5
33
36
317
1.29
0.42
5.4
4.2
7.03
6.22
mmol/l
1.63
31
293
0
15
0.00
0.42
0.0
1.9
—
63.10
—
0
15
0
16
0.00
0.41
0.0
1.5
—
—
—
0
0
21
172
1.32
0.41
8.0
6.2
—
—
—
0
0
0
17
0.00
0.41
0.0
3.2
—
—
—
0
0
21
173
1.31
0.39
2.5
2.5
—
—
—
0
0
9
70
1.33
0.39
2.7
2.3
22.56
24.51
%
—
9
65
10
73
1.43
0.37
2.1
1.9
3.48
3.65
mmol/l
—
10
58
23
268
0.78
0.36
2.4
2.0
—
—
—
0
0
6
44
1.40
0.35
1.0
1.1
—
—
—
0
0
7
56
1.28
0.30
9.1
7.2
105.57
104.25
mmol/l
—
7
56
5
73
0.66
0.27
1.0
1.3
—
—
—
0
0
9
76
1.21
0.26
2.1
1.4
—
—
—
0
0
13
154
0.81
0.22
2.0
1.4
2.27
2.48
g/l
—
8
92
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
7.43
—
0
12
0
12
0.00
0.21
0.0
1.3
—
46.00
—
0
12
67
658
+∞
0.21
23.1
19.9
7.32
6.50
e9/l
2.75
67
652
67
658
+∞
0.21
23.1
19.8
4.65
4.46
e12/l
4.31
67
652
67
657
+∞
0.21
23.1
19.9
276.54
268.15
e9/l
0.55
67
652
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
48.59
—
0
13
28
254
1.18
0.21
2.9
3.3
6.23
6.21
ph
0.03
15
143
0
14
0.00
0.20
0.0
2.6
—
—
—
0
0
16
138
1.21
0.20
3.9
3.7
1.01
1.02
kg/l
—
10
89
37
345
1.16
0.19
4.1
3.3
89.76
68.24
ug/l
0.53
37
327
7
58
1.23
0.19
1.6
1.1
—
—
—
0
0
7
62
1.14
0.18
2.0
1.6
—
—
—
0
0
5
65
0.75
0.18
1.0
1.5
—
—
—
0
0
6
79
0.74
0.16
3.2
3.2
3.37
4.64
e9/l
—
6
71
43
408
1.15
0.16
4.2
4.1
—
—
—
0
0
12
138
0.84
0.14
1.8
1.9
—
—
—
0
0
14
125
1.15
0.11
4.2
3.8
—
—
—
0
0
5
45
1.12
0.10
1.2
1.1
—
—
—
0
0
35
334
1.10
0.09
7.1
6.1
8.44
9.14
umol/l
0.45
35
317
6
74
0.79
0.08
2.2
1.8
—
—
—
0
0
8
73
1.11
0.08
1.5
2.4
—
—
—
0
0
18
174
1.05
0.00
3.9
3.9
0.00
0.00
estimate
—
5
67
31
305
1.03
0.00
3.3
2.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
2.26
—
0
5
5
52
0.96
-0.00
3.0
2.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
221.20
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.3
—
9.88
—
0
9
61
601
1.17
-0.00
14.4
13.0
14.02
18.36
mg/l
0.92
51
473
0
5
0.00
-0.00
0.0
1.4
—
7.86
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.3
—
4.84
—
0
9
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
76
0.91
-0.00
1.4
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
29.40
—
0
5
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
6.99
—
0
7
0
9
0.00
-0.00
0.0
1.9
—
6.82
—
0
9
0
5
0.00
-0.00
0.0
1.2
—
55.20
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
92.43
—
0
7
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.6
—
5.72
—
0
5
0
7
0.00
-0.00
0.0
3.1
—
0.89
—
0
7

Mortality – FinRegistry

↥

This endpoint is excluded (not available in FinRegistry).

Relationships between endpoints

↥

Index endpoint: L12_HIRSUTISM_ADVERSE – Hirsutism, drug-induced

GWS hits: -

This endpoint is excluded (not available in FinRegistry).